Source : Verona Pharma plc
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company that he has purchased a further 25,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) at a total purchase price of £11,750, at a price of 47 pence per Ordinary Share. This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £125,000.
Following the purchase, Dr. Ebsworth will have an interest in the Company of 395,387 Ordinary Shares, representing 0.38% of the Company’s issued share capital.
Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | David Ebsworth |
| 2 | Reason for the notification | |
a) | Position/status | Chairman |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Verona Pharma plc |
| b) | LEI | 213800EVI6O6J3TIAL06 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||
| Identification code | GB00BYW2KH80 | |||
| b) | Nature of the transaction | David Ebsworth purchased 25,000 Ordinary Shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| 47 pence | 25,000 | |||
| d) | Aggregated information | N/A | ||
| - Aggregated volume | ||||
| - Price | ||||
| e) | Dates of the transactions | 14-Nov-19 | ||
| f) | Place of the transactions | London Stock Exchange, AIM | ||
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
| Victoria Stewart, Director of Communications | |
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 3283 4200 |
| Aubrey Powell / George Tzimas (Corporate Finance) |
Mia Gardner (Corporate Broking)